The FDA has approved Caplyta as adjunctive therapy with antidepressants to treat major depressive disorder in adults, ...
Another of the psychiatry drugs Neurocrine Biosciences licensed from Takeda has stumbled in the clinic. | Another of the ...
Lumateperone is approved as an adjunctive treatment for MDD, expanding its indications beyond schizophrenia and bipolar ...
The J&J antipsychotic drug Caplyta won FDA approval for depression, a broader indication that could help the medicine become ...
In everyday language, the word depression is used in diverse ways and can refer to anything from passing feelings of sadness and unhappiness to chronic grief and deep despair. When clinicians and ...
Neurocrine's Phase 2 trial of NBI-1070770 in major depressive disorder missed its main goal but showed good safety and strong Q3 financial results.
BUFFALO, N.Y. — University at Buffalo neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication, often described as a wonder drug, ...
News-Medical.Net on MSN
GeneSight test-guided treatment leads to faster remission and response in patients with depression
Myriad Genetics, Inc., a leader in molecular diagnostic testing and precision medicine, today announced a post-hoc analysis ...
Neuropsychiatric drug development is rife with clinical trial failures, but Alto Neuroscience aims to overcome these hurdles with a precision medicine approach that matches a patient to a drug. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback